About us

The Monoclonal Antibody Core Facillity at the Helmholtz Zentrum München (formerly GSF) was founded in 1990 by Dr. Elisabeth Kremmer and since then has established monoclonal antibodies against more than 2000 targets.

To meet the constantly rising demand for custom-made monoclonal antibodies, we updated the workflow, minimized the numbers of required animals through multi-immunization protocols and introduced advanced automated bead-based flow cytometry technology for high-throughput screening. We are generating up to 100 new antibodies per year, ranging from antibodies against small molecules to cell surface receptors.

We collaborate with scientist at the Helmholtz Zentrum München and with national and international Universities and Research Centers to generate new antibodies and to develop new antibody-based technologies. The Monoclonal Antibody Core Facillity is currently member of theSyNergy Excellence Cluster and the German Center for Neurodegenerative Diseases (DZNE).

In collaboration with an international consortium, we developed a set of antibodies against marker proteins for the homeostatic or disease-associated state of microglia. Antibodies were validated in Western Blot assays and immunoprecipitation assays. Established antibodies are available for the scientific community upon request.